Clearstone and TNT Announce Collaboration
Clearstone Central Laboratories today announced a strategic partnership with express delivery company TNT. The two companies also released a video that outlines the relationship and ongoing efforts to provide innovative and cost-effective solutions for customers.
“Because of cost controls and increasing regulatory challenges, the need to find unique solutions for our customers has never been more important. We are therefore very pleased to be working closely with TNT to open more efficient traffic lanes for our time-sensitive shipments, and to develop new processes and technologies that enable Clearstone to meet the changing needs of our clients," said Lewis Cameron, Clearstone CEO.
“Together we have developed solutions in such areas as temperature controlled packaging that has benefited the entire Clinical Trial logistics supply chain", said Cathy O'Brien, TNT Global Sector Manager of Clinical Research and Pharma. "TNT's flexibility to provide several service layers at transparent pricing levels...helps Clearstone to provide more transparent and cost effective solutions to their customers.”
The video can be viewed on Clearstone’s website:http://www.clearstonelabs.com/news/?doc=multimedia_downloads
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
